This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Clostridium difficile

Authoring team

Clostridioides difficile (previously known as Clostridium difficile) is a species of the genus Clostridia. Some pathogenic forms are associated with the development of pseudomembranous colitis, usually after antibiotic therapy.

  • in the UK, since January 2021 there has been an increase in Clostridioides difficile infections (CDI) for which there is no clear explanation
    • the UKHSA is investigating a newly evolving ribotype (955) which has emerged in England over the last 2 years (total 50 cases)
      • this ribotype may present with severe disease or as a recurrence and has caused significant mortality
      • microbiological sensitivity testing has identified that the ribotype 955 isolates are RESISTANT to treatment metronidazole and therefore the use of this agent will be ineffective for treating CDI

Reference:

  • UK Health Security Agency (18/1/24). Emergence of new Clostridioides difficile ribotype – 955 - update

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.